PFE chart update, Medicine is expensive So essentially, I tried to follow the trends.
When doing so, it does form an interesting pattern.
It almost looks like a long position chance.
It depends on where support lands with price action, and where the trend breakout occurs, as there is a nice gap setup on the charts that puts PFE on a climb and allows it to form a bullish long term trend.
Should trend break down past last support and confirm that underside exit, it would probably signal a bearish move is more likely.
However, It's a neat setup to watch.
good luck
Link to other PFE chart will be attached.
PFE
Pfizer Stock Rises on Report Starboard Takes $1Bln StakePfizer Inc. (NYSE: NYSE:PFE ), once a market darling during the COVID-19 pandemic thanks to its breakthrough vaccine, has seen its stock struggle over the past two years. The shares are trading roughly 30% lower than in 2019 and have faced immense pressure due to declining demand for its COVID-related products and a costly acquisition strategy. However, a new catalyst has emerged that may signal a turning point for the pharmaceutical giant—activist investor Starboard Value has reportedly taken a $1 billion stake in Pfizer (NYSE: NYSE:PFE ), setting the stage for a potential turnaround. Let's dive into the technical and fundamental aspects driving this story.
A Billion-Dollar Vote of Confidence
Starboard Value's stake in Pfizer (NYSE: NYSE:PFE ), valued at roughly $1 billion, is a clear signal that the activist hedge fund believes there is untapped value in the company. Starboard has a track record of targeting underperforming companies and pushing for strategic changes to unlock shareholder value. This time, Starboard appears to be focusing on Pfizer’s management, specifically CEO Albert Bourla, who has been criticized for his acquisition-heavy strategy since taking the helm in 2019.
Under Bourla, Pfizer (NYSE: NYSE:PFE ) has spent close to $70 billion on acquisitions, including the $43 billion deal for Seagen in 2022, focused on cancer drugs. While Pfizer (NYSE: NYSE:PFE ) hoped these moves would diversify its revenue streams beyond COVID-19, many analysts and investors have questioned the returns on these investments, particularly after Pfizer (NYSE: NYSE:PFE ) recently had to recall a sickle cell drug it acquired in the $5 billion Global Blood Therapeutics acquisition. The drug Oxbryta, which brought in only $300 million last year, had to be pulled due to safety concerns, further denting investor confidence.
Starboard’s approach reportedly includes reaching out to Ian Read, Pfizer’s former CEO, and Frank D’Amelio, its former CFO, both of whom had a more disciplined focus on cost management and investment in novel drugs during their tenure. Under Read, Pfizer shares more than doubled, while Bourla’s leadership has coincided with a significant erosion in shareholder value.
To address these challenges, Pfizer (NYSE: NYSE:PFE ) has already initiated a $4 billion cost-cutting program and is planning further reductions. However, more than $100 billion in shareholder value has evaporated since the peak of the pandemic, putting immense pressure on management to act swiftly.
Technical Outlook
From a technical perspective, Pfizer’s stock has been in a downward trend since its pandemic highs in 2021. However, the recent news of Starboard’s involvement has injected new life into the stock, which is up around 3% in premarket trading. This spike is also above key moving averages, suggesting a potential shift in momentum.
The (Relative Strength Index) RSI currently sits at 42.59, which is just below neutral territory. While not yet in the overbought range, this indicates the stock still has room to run, particularly as investor sentiment improves following the Starboard news. The RSI suggests that the stock may be exiting its oversold condition, aligning with a bullish outlook.
Pfizer has been trading in a falling trend pattern, characterized by lower highs and lower lows. However, the recent surge in premarket trading suggests a potential break from this pattern. If the stock can maintain its momentum and break through key resistance levels, we could see a reversal in its overall trend.
NYSE:PFE has moved above several key moving averages, which often serve as support and resistance levels. Breaking above these averages can be a bullish signal for traders, especially in combination with improving fundamentals driven by Starboard’s involvement.
Market Performance vs. Peers
Pfizer's shares have been relatively flat in 2024, underperforming the broader market, which has seen a 21% rise in the S&P 500. This poor performance is in part due to fading COVID-19-related revenues and costly acquisitions that have yet to yield significant returns. The company’s stock is currently about 50% below its pandemic peak.
However, it’s worth noting that while Pfizer (NYSE: NYSE:PFE ) has underperformed, it still maintains a massive market capitalization, and its core pharmaceutical business remains strong. The company’s portfolio includes blockbuster drugs and a robust pipeline of potential therapies, particularly in oncology. Should Starboard’s involvement lead to a more disciplined approach to M&A and cost management, Pfizer could be well-positioned for a resurgence.
Outlook: Can Starboard Revive Pfizer?
While it’s too early to say definitively what Starboard's exact plans are for Pfizer, the involvement of an activist investor of this magnitude is often a positive signal for shareholders. Starboard has historically been successful in unlocking value in companies, and if Pfizer’s management is willing to make the necessary changes, we could see a significant turnaround in its stock price.
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name
during the pandemic, now faces a pivotal moment.
Activist investor Starboard Value has taken a $1 billion
stake, signaling potential changes on the horizon. But
what does this mean for Pfizer's future?
The company that swiftly developed a COVID-19 vaccine
now grapples with declining sales and a tumbling
stock price. Starboard's involvement brings both challenge and
opportunity. Will this be the catalyst for Pfizer's
renaissance or a sign of deeper troubles ahead?
Former Pfizer executives have been approached to assist
in the turnaround effort. Their potential involvement adds
an intriguing layer to this unfolding story. Could
their experience and insight be the key to
unlocking Pfizer's next chapter of success and innovation?
As the pharmaceutical landscape evolves post-pandemic, Pfizer's
response to this pressure could set industry trends.
Cost-cutting, strategic refocusing and potential leadership changes loom
large. How will these moves impact drug development,
patient care, and the broader healthcare ecosystem?
For investors, patients, and industry watchers, Pfizer's
next moves are crucial. Will the company
emerge stronger, leaner, and more innovative? Or will
it struggle to find its footing in a
rapidly changing market? The answers to these questions
could reshape the future of global healthcare.
PFIZER, targeting $50! Upside Prospect ON!PFE weekly data is conveying significant accumulation at the current price range.
Net positive volume has been increasing on a daily basis for the past few days -- in anticipation of the company's incoming price growth, long term.
The stock is currently sitting at 78.6 FIB level -- a discounted level where buyers converge.
Expect some significant bounce from the current range with initial target to $50.
Weekly higher lows on histogram has been registered. Trend shift is about to commence.
First Bubble up volume appearance in almost 2 months.
Spotted at 38.0
TAYOR
Safeguard capital always.
PFE (Y24.P3.E1). Sideways as part of wave 3 to 4Hi traders,
My thoughts on Pfizer to bottom out.
My level of interest is based on my common values for Elliott wave count based on a few assumptions. If it plans out, we will look for a long.
For now, expect a breakdown with this rising channel as the LH and LL overlap, bearish in nature.
All the best,
S.SAri
PFE - Will The Strong Downtrend Ever Be Retested? My thoughts showing how an extended bear move could result in the downward test of a previous bear trend line
I do expect however that one of the green trend lines will hodl so I have put price labels on each of those. It is more likely to continue up than to make this horrid move.
Imagine it going down to $3!
MRNA Taking Profit, Watching for a add LONG after a pullback.MRNA has been on fire since the earnings beat 4 weeks ago and has added 60% to its market cap
in the past three months. It compares well with NVAX which as a prior penny stock has more
volatility and upside potential. In general vaccine stocks are performing well as COVID RSV
and influenza vaccines are active in research are Viral Hepatitis vaccine enhancements and
the drive for an HIV vaccine.
MRNA is strong and perhaps becoming overbought. The mass index indicator has topped and
maybe falling to the trigger line. I will take a one- third partial off my position here
and wait for a pullback with reversal to add back into the position at a lower price.
The tandem of MRNA and NVAX has been very profitable for me. Careful in trade management
will help me keep it that way.
NVAX pushed to bottom of its channel LONGNVAX powered off its earnings and a news catalyst and is overdue now for a correction. While in
an ascending channel NVAX is now at the bottom of the channel perhaps due to the general
market moves this week. From here it can move up in the channel or breakdown and fall into
a significant correction from the uptrend since May 10th. I am bullish on NVAX and have
a prior perspective of an insider. I have realized profit six figures from my call options for
January 2025 and have a large number remaining in the trade. At this juncture, I will watch
for NVAX to move up in the channel and take a trade of shares and some call options
for 15.00 expiring in June 2025 to take advantage of long term capital gains on the options.
The FDA is currently reviewing some COVID vaccine data which is particularly relevant to
NVAX. The volume profile has a shelf at 14.25 which will be my stop loss on the shares.
The options will have a 20% stop loss. Considering the level from which NVAX has fallen over
a period of some period there is great potential in my opinion.
Pfizer !!! low risk , 20% Gain till next month ?? Hello everyone, today I want to discuss Pfizer's stock which experienced a 58% correction from its peak price and is currently trading around $26. I believe this stock has a lot of potential for both scalpers and long-term investors. With a dividend yield of 6.65% at this price, it's an attractive investment option. Additionally, the earnings report due this week could boost the stock price to $30 by next month. You can refer to the chart for trade stop and stop-loss points.
Disclaimer: This information or service is for informational purposes only and is not
intended to be personal financial advice
#pfizer
Trade Like A Sniper - Episode 16 - Pfizer - (5th June 2024)This video is part of a video series where I backtest a specific asset using the TradingView Replay function, and perform a top-down analysis using ICT's Concepts in order to frame ONE high-probability setup. I choose a random point of time to replay, and begin to work my way down the timeframes. Trading like a sniper is not about entries with no drawdown. It is about careful planning, discipline, and taking your shot at the right time in the best of conditions.
A couple of things to note:
- I cannot see news events.
- I cannot change timeframes without affecting my bias due to higher-timeframe candles revealing its entire range.
- I cannot go to a very low timeframe due to the limit in amount of replayed candlesticks
In this session I will be analyzing PFE (Pfizer), starting from the 4-Month chart.
- R2F
Pfizer implements $1.5bn cost-cutting initiative. Idea 27/05/24Pfizer Inc. (PFE) has announced a new multi-year plan to reduce operational costs by approximately 1.5 billion USD by the end of 2027. This initiative is in addition to a previously announced 4 billion USD cost reduction strategy in response to decreased investments and a sharp decline in sales from its COVID-19 vaccine. Amid these challenges, Pfizer has actively restructured its operations, including acquiring cancer drug manufacturer Seagen for 43 billion USD, aiming to diversify and strengthen its product portfolio.
Despite these financial adjustments, Pfizer has raised its full-year earnings forecast following better-than-expected earnings in Q1. These results were partly attributed to the successful implementation of cost-saving measures. To bolster its financial standing, the company focuses on operational efficiency, restructuring its network, and enhancing its product portfolio.
Given this backdrop, let's examine the potential trading opportunities for Pfizer Inc. (NYSE: PFE):
On the Daily (D1) timeframe, Pfizer's stock shows a resistance level at 29.65 USD and support at 28.45 USD. The resistance line of the ongoing downtrend has been breached, suggesting a potential shift in market sentiment. If the trend reverses downward, a possible target might be 25.30 USD.
If the current uptrend persists, a short-term target is 31.90 USD upon rebounding from the 29.65 USD resistance level. For a medium-term strategy, the stock price could reach 34.10 USD if the upward momentum continues.
—
Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews.
The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Pfizer Wins $107.5 Million From AstraZeneca in US Cancer DrugPfizer ( NYSE:PFE ) has won $107.5 million in damages from AstraZeneca in a US cancer drug patent trial. A Delaware federal jury found that AstraZeneca's lung cancer drug Tagrisso violated its Wyeth unit's patent rights. The jury agreed that AstraZeneca's drug infringed two patents covering methods for treating cancer with the breast-cancer drug Nerlynx, which is sold by Puma Biotechnology.
Puma licenses the patents from Pfizer ( NYSE:PFE ) to make its drug. AstraZeneca, which earned AstraZeneca nearly $5.8 billion in revenue last year, denied infringing the patents and argued they are invalid. Pfizer ( NYSE:PFE ) is no longer a plaintiff in the case. A separate bench trial on some of AstraZeneca's remaining defenses is set to be held in June, which could result in a ruling that negates the verdict.
Technical Outlook
Pfizer ( NYSE:PFE ) closed Friday's trading at $28.64 down by 0.97%. The stock has a Relative Strength Index (RSI) of 64.11 which is liable for further growth. Pfizer ( NYSE:PFE ) stock is set to rise from its Falling Wedge Pattern which started from the 6th of January, 2024.
BMY- a large cap pharm loosing market cap SHORTBMY is here on the daily chart. The double top and death cross of the EMA moving averages
makes for a strong candidate to short with shares or take put options. A comparsion of the
most recent earnings report with the previous one sixty days earlier tells most of the story.
The dual time frame RSI indicator shows ongoing wekaness. I will short BMY here and take some
call options as well. I am in LLY long in a big position. This will be a race in opposite directions
for two large cap pharmaceuticals.
PFE potential buy setupReasons for bullish bias:
- The price has broken the downtrend trendline
- An entry at the lower highs (LH) breakout will provide further confirmation
- Currently, the price is in a consolidation phase
Here are the recommended trading levels:
Entry Level(Buy stop): 30.18
Stop Loss Level: 25.26
Take Profit Level 1: 35.1
Take Profit Level 2: 40.02
Take Profit Level 3: Open
PFE potential Buy setupReasons for bullish bias:
- Entry at accumulation phase breakout
- Bullish Harmonic XABCD pattern on weekly
- Strong weekly Bullish divergence
- Price broke strong downtrend trendline
- Strong bullish weekly candles at support
- Positive Earnings
Here are the recommended trading levels:
Entry Level(CMP): 28.91
Stop Loss Level: 24.65
Take Profit Level 1: 33.17
Take Profit Level 2: 37.43
Take Profit Level 3: Open
Pfizer Surges as Earnings Soar Above ExpectationsPfizer Inc. ( NYSE:PFE ) sent shockwaves through the market with a stunning first-quarter performance, catapulting its stock price upward following a robust quarterly beat that surpassed analysts' expectations by a wide margin.
The pharmaceutical giant reported adjusted earnings of 82 cents per share, significantly outpacing the forecasted 51 cents per share, and raking in $14.88 billion in revenue, well above the anticipated $13.87 billion. This impressive feat marks a stark turnaround from the previous year's earnings of $1.23 per share on $18.49 billion in sales.
Investors reacted positively to Pfizer's optimistic outlook for the year, as the company raised its earnings guidance and maintained its sales forecast. With a projected adjusted profit range of $2.15 to $2.35 per share and sales expected to reach between $58.5 billion and $61.5 billion, Pfizer is poised for a strong fiscal year ahead.
Key drivers behind Pfizer's stellar performance include aggressive cost-cutting measures and resilient demand for its COVID-19 products, particularly its vaccine Comirnaty, developed in collaboration with BioNTech. Despite a significant drop in sales of the oral antiviral Paxlovid, which fell 50% to $2.04 billion, Pfizer remains optimistic about the prospects of its COVID portfolio, expecting $8 billion in combined sales from its COVID-19 products.
The success of Pfizer's strategic acquisitions, notably the $43 billion deal for Seagen, is evident in the robust sales of cancer treatment Padcev and the continued growth of its pipeline. However, challenges persist, as sales of targeted cancer therapy Adcetris fell short of expectations, underscoring the need for sustained new launch performance.
Attention is also focused on Pfizer's RSV vaccine, which has faced stiff competition from a rival shot by GSK. Despite lower-than-anticipated sales of Abrysvo, Pfizer ( NYSE:PFE ) remains committed to advancing its respiratory syncytial virus (RSV) vaccine portfolio.
Analysts remain cautiously optimistic about Pfizer's trajectory, with JP Morgan's Chris Schott emphasizing the importance of stronger new launch performance and pipeline progress in reshaping investor sentiment.
FDA Approves Pfizer’s First Gene TherapyIn a landmark decision, the Food and Drug Administration (FDA) has given its stamp of approval to Pfizer's groundbreaking gene therapy for hemophilia B, marking a pivotal moment in the field of genetic medicine. Hemophilia B, a rare inherited bleeding disorder affecting thousands in the U.S., has long posed significant challenges for patients and caregivers due to its debilitating nature and the cumbersome treatment regimens it necessitates.
Unveiling Beqvez:
Pfizer's newly approved gene therapy, Beqvez, heralds a paradigm shift in hemophilia B treatment. Unlike conventional methods that require frequent infusions of factor IX, Beqvez offers a one-time solution, empowering patients to produce the crucial clotting factor independently. This innovative approach not only promises to alleviate the burden of regular treatments but also holds the potential to prevent and control bleeding more effectively.
Transformative Impact:
The approval of Beqvez represents a ray of hope for individuals grappling with hemophilia B, offering a lifeline towards improved quality of life and reduced medical complexities. Dr. Adam Cuker, from Penn Medicine’s Comprehensive and Hemophilia Thrombosis Program, underscores the transformative potential of Beqvez, emphasizing its ability to mitigate both medical and treatment-related challenges over the long term.
Pfizer's Strategic Maneuver
For Pfizer ( NYSE:PFE ), the approval of Beqvez marks a strategic triumph in its quest to diversify beyond the realm of COVID therapeutics. With a keen focus on gene and cell therapies, Pfizer ( NYSE:PFE ) is positioning itself at the forefront of medical innovation, aiming to redefine the treatment landscape across various disease domains. The company's investment in Beqvez underscores its commitment to pioneering solutions that address unmet medical needs and enhance patient outcomes.
Navigating Challenges:
While the approval of Beqvez heralds a new era in hemophilia B treatment, it also presents formidable challenges. The exorbitant price tag of $3.5 million raises concerns about accessibility and affordability, echoing debates surrounding the broader issue of healthcare equity. Furthermore, logistical hurdles and adoption barriers may impede widespread uptake, underscoring the need for comprehensive strategies to ensure equitable access to this groundbreaking therapy.
Looking Ahead:
As Pfizer ( NYSE:PFE ) embarks on this groundbreaking journey with Beqvez, the company's pipeline continues to brim with promise. From experimental antibodies to gene therapies targeting other genetic disorders like Duchenne muscular dystrophy, Pfizer remains at the vanguard of medical innovation, driving forward the frontier of personalized medicine. As the healthcare landscape evolves, Beqvez stands as a beacon of hope, illuminating a path towards a future where genetic therapies revolutionize the treatment paradigm, one patient at a time.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending
Despite short-term challenges like revenue and earnings declines in the current quarter, Pfizer (PFE) maintains a positive long-term growth trajectory. With optimistic earnings estimates for the full fiscal year, consistent EPS beats, and a discounted valuation relative to peers, Pfizer represents an attractive investment opportunity.
Trade Idea: Buy Pfizer (PFE)
Long-term growth potential remains strong despite short-term setbacks.
Positive earnings outlook for the full fiscal year indicates resilience.
Consistent EPS beats highlight Pfizer's ability to manage its bottom line effectively.
Discounted valuation compared to industry peers suggests potential for stock price appreciation.
Consider a medium to long-term investment horizon to capture Pfizer's growth prospects and maximize returns.
SasanSeifi 💁♂ PFE /DAILY ⏭ $28 /$30Hey there,✌
NYSE:PFE In the daily timeframe, as observed, the price is currently fluctuating within the $25 range following a prolonged downtrend. The long-term trendline has been broken, and we can consider the following scenario: if the demand range is maintained, the price may experience positive fluctuations up to the $28 range. Then, if the $28 ceiling is breached and stabilizes above it, we may witness an upward trend and a new higher HIGH beyond the $28 ceiling. The desired targets in the long term and potential trends are also indicated in the attached image. The $25 demand range is crucial for the envisaged scenario. Moreover, if the price penetrates below the $25 range, the likelihood of further correction increases.
This is not financial advice. Always do your research before making any investment decisions.❗
Sure, if you have any more questions or need further clarification, feel free to ask. I'm here to help!✌
if you found my analysis helpful, I would appreciate it if you could show your support by liking and commenting. Thank you!🙌